Agonistic properties of cannabidiol at 5-HT1a receptors

Neurochemical Research

Volumn 30, Issue 8, 2005, Pages 1037-1043

  Russo, Ethan B ^a   Burnett, Andrea ^a   Hall, Brian ^a   Parker, Keith K ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

cAMP; Cannabidiol; Cannabis; G Proteins; Marijuana; Serotonin; THC

Indexed keywords

CANNABIDIOL; CANNABINOID RECEPTOR; CANNABIS; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TETRAHYDROCANNABINOL;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BINDING, COMPETITIVE; CANNABIDIOL; CHO CELLS; CRICETINAE; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, CELL SURFACE; SEROTONIN AGONISTS;

ANIMALIA; CANNABIS; CANNABIS SATIVA;

EID: 27644440716     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-005-6978-1     Document Type: Article

References (43)

1. E. B. Russo 2003 Introduction: Cannabis: from pariah to prescription J. Cann. Therap. 3 3-4 1 29
2. Pertwee, R. G. 2004. The pharmacology and therapeutic potential of Cannibidiol. Pages 1-52, in DiMarzo, V. (ed.), Cannabinoids. Kluwer Academic/Plenum Publishers
3. A. W. Zuardi F. S. Guimaraes 1997 Cannabidiol as an anxiolytic and antipsychotic M. L. Mathre Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana Jefferson NC: McFarland 133 141
4. E. A. Carlini J. M. Cunha 1981 Hypnotic and antiepileptic effects of cannabidiol J. Clin. Pharmacol. 21 8-9 Suppl 417S 427S
5. A. J. Hampson M. Grimaldi J. Axelrod D. Wink 1998 Cannabidiol, (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc. Natl. Acad. Sci. USA. 95 14 8268 73
6. T. Iuvone G. Esposito R. Esposito R. Santamaria M. Di Rosa A. A. Izzo 2004 Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on beta-amyloid-induced toxicity in PC 12 cells J. Neurochem. 89 134 141
7. A. N. Nicholson C. Turner B. M. Stone P. J. Robson 2004 Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults J. Clin. Psychopharmacol. 24 3 305 313
8. J. [tmp] McPartland V. Di Marzo L. De Petrocellis A. Mercer M. Glass 2001 Cannabinoid receptors are absent in insects J. Comp. Neurol. 436 4 423 9
9. R.G. Pertwee 1997 "Pharmacology of cannabinoid CB1 and CB2 Receptors" Pharmacol. Therap. 74 2 129 180
10. B. F. Thomas A. F. Gilliam D. F. Burch M. J. Roche H. H. Seltzman 1998 "Comparative receptor binding analysis of cannabinoid agonists and antagonists" J. Pharm. Exp. Therap 285 1 285 292
11. F. Petitet B. Jeantaud M. Reibaud A. Imperato M. C. Dubroeueq 1998 "Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity at delta 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors" Life Sci. 63 1 PL1 PL6
12. J. M. [tmp] McPartland E. B. Russo 2001 Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? J. Cannabis Therap. 1 3-4 103 132
13. E. B. Russo 2001 Hemp for headaches: An in-depth historical and scientific review of cannabis in migraine treatment J. Cannabis Therap. 1 2 21 92
14. E. B. Russo 2004 Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol. Lett. 25 1-2 31 39
15. M. D. Ferrari P. R. Saxena 1995 5-HT1 receptors in migraine pathophysiology and treatment Eur. J. Neurol. 2 5 21
16. M. Hershkowitz 1978 "The effect of in vivo treatment with (-) /delta 1-tetrahydrocannabinol, and other psychoactive drugs on the in vitro uptake of biogenic amines" Adv. Biosci. 22-23 351 358
17. P. J. Cowen 2000 Psychopharmacology of 5-HT1a receptors Nuc. Med. Biol. 27 437 439
18. N. M. Barnes T. Sharp 1999 A review of central 5-HT receptors and their function Neuropharmacol. 38 8 1083 1152
19. A. Fargin J. R. Raymond M. J. Lohse B. K. Kobilka M. G. Caron R. J. Lefkowitz 1988 The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1a receptor Nature 335 358 360
20. D. L. Nelson P. J. Monroe G. Lambert H. I. Yamamura 1987 [3H]Spiroxatrine labels a serotonin 1a-like site in rat hippocampus" Life Sci. 41 1567 1576
21. J. T. Weber M.-F. O'Connor K. Hayataka N. Colson R. Medora E. B. Russo K. K. Parker 1997 Activity of parthenolide at 5HT2a receptors J. Nat. Prods. 60 6 651 653
22. R. A. Glennon M. Teitler E. Sanders-Bush 1992 Hallucinogens and serotonergic mechanisms NIDA Res. Monographs 119 131 135
23. P. B. Hedlund M. J. Carson J. G. Sutcliffe E. A. Thomas 1999 Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine 7 receptors Biochem. Pharmacol. 58 1807 1813
24. D. L. Boger J. E. Patterson Q. Jin 1998 Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide Proc. Natl. Acad, Sci, USA 95 8 4102 4107
25. J. F. Cheer A. K. Cadogan C. A. Marsden K. C. Fone D. A. Kendall 1999 "Modification of 5HT2a receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors" Neuropharmacol. 38 4 533 545
26. M. G. Devlin A. Christopoulos 2002 "Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum" J. Neurochem. 80 6 1095 1102
27. T. C. Ortiz M. C. Devereaux K. K. Parker 2000 Structural variants of a human 5-HT1a receptor intracellular loop 3 peptide Pharmacol. 60 195 202
28. D. Julius K. N. Huang T. J. Livelli R. Axel T. M. Jessel 1990 The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors" Proc. Natl. Acad. Sci.USA 87 928 932
29. B. Hall A. Burnett C. Halley L. Parker E. Russo K. K. Parker 2004 Pharmacology of cannabidiol at serotonin receptors Proc. West. Pharmacol. Soc. 47 43 (M24)
30. P. A. Pierce S. J. Peroutka 1989 Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex" Psychopharmacol. 97 118 122
31. M. M. Bradford 1976 A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 248 254
32. T. Wieland K. H. Jacobs 1994 Measurement of receptor-stimulated guanosine 5'-O-(gamma-thio)triphosphate)binding by G proteins Meth. Enzymol. 237 3 27
33. S. R. Wachtel M. A. ElSohly R. A. Ross J. Ambre H. de Wit 2002 Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans Psychopharmacology 161 331 339
34. J. M. [tmp] McPartland E. B. Russo 2001 Cannabis and cannabis extracts: Greater than the sum of their parts? J. Cann. Therap. 1 3-4 103 132
35. E. B. Russo J. M. [tmp] McPartland 2003 Cannabis is more than simply Delta(9)-tetrahydrocannabinol Psychopharmacology (Berl.) 165 4 431 2
36. J. S. Berman C. Symonds R. Birch 2004 Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial Pain 112 3 299 306
37. W. Notcutt M. Price R. Miller S. Newport C. Phillips S. Simmonds C. Sansome 2004 Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies Anaesthesia 59 440 452
38. D. T. Wade P. Makela P. Robson H. House C. Bateman 2004 Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult. Scler. 10 4 434 41
39. D. T. Wade P. Robson H. House P. Makela J. Aram 2003 A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clin. Rehabil. 17 18 26
40. C. M. Brady R. DasGupta C. Dalton O. J. Wiseman K. J. Berkley C. J. Fowler 2004 An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis Mult. Scler. 10 425 433
41. I. G. Karniol I. Shirakana N. Kasinski A. Pfeferman E. A. Carlini 1974 "Cannabidiol Interferes With the Effects of Delta 9-Tetrahydrocannabinol in Man" Eur. J. Pharmacol. 28 1 172 177
42. T. Bisogno L. Hanus L. De Petrocellis S. Tchilibon D. E. Ponde I. Brandi A. S. Moriello J. B. Davis R. Mechloulam V. DiMarzo 2001 Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 134 4 845 852
43. A.C. Howlett 2002 "International union of pharmacology XXVII classification of cannabinoid receptors" Pharmacol. Rev. 54 2 161 202